Молекулярно-генетические основы наследственных форм болезни Паркинсона
Диссертация
Данная работа, включившая молекулярно-генетический анализ генов SNCA, PARK2, LRRK2, GBA у пациентов с БП, является первым комплексным исследованием генетических основ наследственных форм БП в России. Впервые описан спектр мутаций в генах LRRK2 и PARK2 у пациентов с БП в России. У пациентов с семейной формой БП впервые в мире описана мутация Т4838С (VI61 ЗА), приводящая к развитию… Читать ещё >
Список литературы
- Ахмедова (Пчелина С.Н.). Молекулярно-генетические основы предрасположенности к болезни Паркинсона. Автореф. на соискание к-та биол. наук. СПб. 2000. — 19с
- Баранов B.C. Генетический паспорт основа индивидуальной и предиктивной медицины. — СПб.: Н-Л, 2009. — 528с
- Бочков Н.П., Клиническая генетика. М.: ГЭОТАР-МЕД, 2002.448с
- Букина Т.М. Биохимическая и молекулярно-генетическая характеристика болезни Гоше у российских пациентов.- Автореф. на соискание к-та биол. наук. Москва. 2005.-22 с
- Букина Т.М., Цветкова И. В. Характеристика мутаций гена кислой betta-D-глюкозидазы (GBA) среди 68 российских пациентов с болезнью Гоше // Биомедицинская химия. 2007. — Т.53, № 5. — С.593 — 602
- Варга О.Ю. Влияние метилпреднизолона и циклофосфана in vitro на активность апоптоза лимфоцитов периферической крови при системной красной волчанке // Российский биомедицинский журнал Med-line.ru. 2007, Т.8, № 47.-С.518−525
- Айламазян Э. К., Баранов В. С. Пренатальная диагностика наследственных и врожденных болезней. М.: МЕДпресс-информ, 2007. -416с.
- Вахарловский В. Г., Романенко О. П., Горбунова В. Н. Генетика в практике педиатра. — СПб., 2009. — С. 251—253
- Внуков В.В., Даниленко А. О., Головатенко О. И., Ананян A.A., Милютина Н. П. Апоптоз и структурное состояние мембран лимфоцитов при болезни Пркинсона// Валеология. 2011. — Т. 1. — С.45−50
- Гинтер Е. К. Наследственные болезни в популяциях человека. М.: Медицина, 2002. — 304с
- Голубев, В.Л., Левин Я. И., Вейн A.M. Болезнь Паркинсона и синдром паркинсонизма. М.: МЕДпресс, 2000. — 416 с
- Горбунова В. Н., Пчелина С. Н., Шварцман А. Л. Введение молекулярную медицину, СПб., Издательство политехнического университета, 2011. 214 с
- Гордеева А. В., Лабас Ю. А., Звягильская Р. А. Апоптоз одноклеточных организмов: механизмы и эволюция// Биохимия. 2004. -Т.69, № 10. — С. 1301−131
- Григорьев М.Ю., Имянитов E.H., Хансон К. П. Апоптоз в норме и патологии// Медицинский академический журнал. 2003. — Т.З. — С.3−11
- Давыдова A.B. ЛИЗОСОМНЫЕ БОЛЕЗНИ НАКОПЛЕНИЯ: БОЛЕЗНЬ ГОШЕ// Сибирский медицинский журнал. 2009 — Т.5. — С. 9−14
- Иванов В.И., Киселев Л. Л. Геномика медицине. — М.: ИКЦ «Академкнига», 2005. — 389с
- Иванова О.Н., Якимовский А. Ф., Пчелина С. Н. Молекулярно-генетический анализ ранних форм болезни Паркинсона // Ученые записки СПбГМУ им. акад.И. П. Павлова. 2005. — T. XII, № 4. — С. 105−106
- Ижевская В. Л., Иванов В. И. Геномика и основные биоэтические проблемы медицинской генетики // Вестник РАМН. 2001. — Т. 10. — С.59−64
- Ижевская, В.Л. Этические и правовые аспекты генетического тестирования и скрининга// Медицинская генетика. 2006. — Т.5. — С. 3−8
- Иллариошкин С.Н. Конформационные болезни мозга. М.: Янус-К, 2002.-246с
- Иллариошкин С.Н. Течение болезни Паркинсоан и подходы к ранней диагностике // В руководстве для врачей Болезнь Паркинсона и расстройства движений. Под ред. С. Н. Иллариошкина, О. С. Левина. М.: ЗАО «Серебряные нити», 2011. — С.41−47
- Иллариошкин С.Н., Иванова-Смоленская И. А. Дрожательные гиперкинезы. М.:Атмосфера, 2011. — 354с •
- Иллариошкин С.Н., Иванова-Смоленская И.А., Маркова Е. Д. ДНК-диагностика и медико-генетическое консультирование в неврологии. М.: Медицинское информационное агентство, 2002. — 591с
- Иллариошкин С.Н. Современные подходы к лечению болезни Паркинсона // Атмосфера. Нервные болезни. 2004. — Т.4. — С. 14−21
- Катунина Е.А., Титова Н. В., Авакян Г. Н. Методы диагностики болезни Паркинсона на ранних стадиях // Журнал неврологтт и психиатрии им. С.С.Корсакова- 2010. Т. 12. -С.112−118
- Крыжановский Г. Н. Болезнь Паркинсона (этиология, патогенез, клиника, диагностика, лечение, профилактика). М.: Медицина, 2002. — 336с
- Лаврик И., Краммер П. Решение «жизнь-или-смерть» в системе CD95: основне про- и антиапоптозные модуляторы" // ACTA NATURAE.-2009. -T.l. -С.80−83
- Левин О.С., Федорова Н. В. Болезнь Паркинсона. М.: МЕДпресс-Информ, 2012. -351с
- Левин, О.С., Докадина Л. В. Эпидемиология паркинсонизма и болезни Паркинсона // Неврологический журнал. 2005. — Т. 10, № 5. — С. 41−49
- Литвиненко И.В. Болезнь Паркинсона. М.: Миклош, 2006.216с
- Пчелина С.Н. Альфа-синуклеин как биомаркер болезни Паркинсона // Анналы клинической и экспериментальной неврологии. -2011 В. Т.6. — С. 46−51
- Пчелина С.Н., Иванова О. Н., Емельянов А. К., Якимовский А. Ф. Клиническое течение ЬККК2-ассоциированной болезни Паркинсона // Журнал неврологии и психиатрии им. С. С. Корсакова. 20 116. — Т. 111, № 12. — С.56−62
- Пчелина С.Н., Иванова О. Н., Емельянов А. К., Якимовский А. Ф., Шварцман A.JI. Мутации в гене LRRK2 у больных с болезнью Паркинсона в России // Медицинская генетика. 2006. — Т.5, № 2. — С.48−51
- Пчелина С.Н., Усенко Т. С., Боганькова H.A., Якимовский А. Ф., Емельянов А. К., Вавилова Т. В., Шварцман A.JI. Повышенный спонтанный апопотоз лимфоцитов у пациентов с болезнью Паркинсона // Медицинская иммунология, 2012а.- Т.14, № 1−2, — С.149−152
- Пчелина С.Н., Якимовский А. Ф., Шварц Е. И. Наследственные основы болезни Паркинсона // Медицинская генетика. 2003. — Т.9, №. -С.411−425
- Семенова Е.В., Шадрина М. И., Сломинский П. А., Иллариошкин С. Н., Багыева Г. Х., Карабанов A.B., Иванова-Смоленская И.А., Лимборская
- С.А. Анализ дозы гена а-синуклеина при аутосомно-доминантной форме болезни Паркинсона // Генетика. 2009. — Т.45, № 4.-С. 1−3
- Скоромец A.A., Скоромец А. П., Скоромец Т. А. Нервные болезни. -М. :МЕДпресс-информ, 2005. 544с
- Сломинский П.А., Милосердова О. В., Попова С. Н., и др. Анализ делеционных мутаций в гене PARK2 у больных идиопатической формой болезни Паркинсона // Генетика. 2003. — Т.39. — С.223−228
- Степанов В.А. Геномы, популяции, болезни: этническая геномика и персонифицированная медицина // Acta Naturae. 2010. — Т. 2, № 4. — С. 1833
- Угрюмов М. В. Нейродегенеративные заболевания. Фундаментальные и прикладные аспекты. М.: Наука, 2010. — 447с
- Усенко Т.С., Емельянов А. К., Якимовский А. Ф., Боганькова H.A., Вавилова Т. В., Шварцман A.JI., Пчелина С. Н. Апоптоз лимфоцитов периферической крови у пациентов с Г11ЯК2-ассоциированной формой болезни Паркинсона // Цитология. 2012. — Т.54, № 1. — С.44−48
- Федотова Е.Ю., Чечеткин А. О., Шадрина М. И., Сломинский П. А., Иванова Смоленская И.А., Иллариошкин С. Н. Транскраниальная сонография при болезни Паркинсона // Журнал неврологии и психиатрии им. С. С. Корсакова. — 2011. — Т. 111, №.1. — С. 49−55
- Шадрина М.И. Молекулярно-генетические основы болезни Паркинсона Автореф. на соискание д-ра биол. наук. Москва. 2011. — 48с
- Шадрина М. И.- Иллариошкин С.Н.- Багыева Г. X.- Беспалова Е.
- Adam D. Pesticide use linked to Parkinson’s disease // Nature. 2000. — Vol.408.-P.125
- Aerts M.B., Esselink R.A., Abdo W.F., Bloem B.R., Verbeek M.M. CSF a-synuclein does not differentiate between parkinsonian disorders // Neurobiol Aging. 2012. -Vol.33, № 2. -P.430
- Aharon-Peretz J., Rosenbaum H., Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson’s disease in Ashkenazi Jews // N Engl J Med. 2004. — Vol.351, № 19. -P.1972−7
- Akhmedova (Pchelina) S., Yakimovsky A., Schwartz E. Paraoxonase 1 Polymorphism Met-Leu 54 Is Associated with Parkinson’s Disease // J Neurol Sci. 2001, — Vol.184.-P. 179−182
- Akhmedova S., Anisimov S., Yakimovsky A., Schwartz E. Gln-Argl91 polymorphism of paraoxonase and Parkinson’s disease // Human Heredity.- 1999.-Vol. 49.-P. 178−180
- Aktas O., Ullrich O., Infante-Duarte C., Nitsch R., Zipp F. Neuronal damage in brain inflammation // Arch Neurol. 2007. — Vol.64, № 2. — P. 185−9
- Alberio T., Bossi A., Milli A., Parma E., Gariboldi M., Tosi G., Lopiano L., Fasano M. Proteomic analysis of dopamine and alpha-synuclein interplay in a cellular model of Parkinson’s disease pathogenesis // FEBS J. -2010. Vol.277. — P.4909−4919
- Ardestani A., Yazdanparast R., Nejad A.S. 2-Deoxy-D-ribose-induced oxidative stress causes apoptosis in human monocytic cells: prevention by pyridoxal-5'-phosphate // Toxicol In Vitro. 2008. — Vol.22, № 4. — P.968−79
- Ascherio A., Zhang S.M., Hernan M.A., Kawachi I., Colditz G.A., Speizer F.E., Willett W.C. Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women // Ann Neurol. 2001. — Vol.50. — P.56−63
- Autere J.M., Moilanen J.S., Myllyla V.V., Majamaa K. Familial aggregation of Parkinson’s disease in Finnish population // J Neurol Neurosurg Psychiatry. 2000. — Vol.69, № 1. — P. 107−109
- Ayub A., Mackness M.I., Arrol S., Mackness B., Patel J., Durrington P.N. Serum paraoxonase after myocardial infarction // Arterioscler Thromb Vase Biol. 1999. — Vol.19.-P.330−5
- Banerjee R., Beal M.F., Thomas B. Autophagy in neurodegenerative disorders: pathogenetic roles and therapeutic implications // Trands in Neurosci. -2010. Vol.33. -P.541−549
- Bas J., Calopa M., Mestre M. Lymphocyte populations in Parkinson’s disease and in rat models of parkinsonism // J Neuroimmunol. 2001. — Vol.113, № 1. — P.146−152
- Battisti C., Formichi P., Tripodi S.A., Mangiavacchi P., Tosi P., Federico A. Increased apoptotic response to 2-deoxy-D-ribose in ataxia-telangiectasia//J Neurol Sci. 1996. — Vol.144, № 1−2. -P. 128−34
- Battisti C., Formichi P., Radi E., Federico A. Oxidative-stress-induced apoptosis in PBLs of two patients with Parkinson disease secondary to alpha-synuclein mutation//J Neurol Sci. 2008. — Vol.15, № 267. — P. 120−124
- Beck G., Brinkkoetter P., Hanusch C., Schulte J., van Ackern K., van der Woude F.J., Yard B.A. Clinical review: immunomodulatory effects of dopamine in general inflammation // Crit. Care. 2004. — Vol.8. — P.485−491
- Behnke S., Schroder U., Berg D. Transcranial sonography in the premotor diagnosis of Parkinson’s disease // Int Rev Neurobiol. 2010. — Vol.90. -P.93−106
- Bekris L.M., Mata I.F., Zabetian C.P. The genetics of Parkinson’s disease // J Geriatr Psychiatry Neurol. 2010. — Vol.23. — P.228−242
- Bennett D.A., Beckett L.A., Murray A.M., Shannon K.M., Goetz C.G., Pilgrim D.M., Evans DA. Prevalence of Parkinsonian Signs and Associated Mortality in a Community Population of Older People // N. Engl. J.Med. 1996. -Vol. 334.-P. 71−76
- Berg D., Merz B., Reiners K., Naumann M., Becker G. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson’s disease // Mov Disord. 2005. — Vol.20. — P.383−5
- Besser M.J., Ganor Y., Levite M. Dopamine by itself activates either D2, D3 or D1/D5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNFalpha or both // J. Neuroimmunol. 2005. -Vol.169. -P.161−171
- Beyer K. Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers // Acta Neuropathol. 2006. -Vol.112, № 3, — P.237−51
- Bisaglia M., Greggio E., Marie D., Miller D.W., Cookson M.R., Bubacco L. a-Synuclein overexpression increases dopamine toxicity in BE (2)-M17 // Cells BMC Neuroscience. 2010. — Vol. 11. — P. 41
- Bisaglia M., Mammi S., Bubacco L. Structural insights on physiological functions and pathological effects of alpha-synuclein // FASEB J. -2009, — Vol.23. -P.329−40
- Blandini F., Sinforiani E., Pacchetti C., Samuele A., Bazzini E., Zangaglia R., Nappi G., Martignoni E. Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease // Neurology. 2006. — Vol.66, № 4. -P.529−34
- Blandini F., Mangiagalli A., Cosentino M., Marino F. Peripheral markers of apoptosis in Parkinson’s disease: the effect of dopaminergic drugs // AnnN Y Acad. Sei. 2003. — Vol.1010. — P. 675−678
- Bodin L., Beaune P.H., Loriot M.A. Determination of Cytochrome P450 2D6 (CYP2D6) Gene Copy Number by Real-Time Quantitative PCR // J Biomed Biotechnol. 2005. — Vol.3. — P.248−53
- Bonifati V., Rizzu P., van Baren M.J., Samuele A., Bazzini E., Zangaglia R., Nappi G., Martignoni E. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism // Science. 2003. -Vol.299. -P.256−259
- Bossy-Wetzel E., Schwarzenbacher R., Lipton S.A. Molecular pathways to neorodegeneration // Nature Medicine. 2004. — Vol.10. -P.S2-S9
- Bower J.A., Dickson D.W., Taylor L., Maraganore D.M., Rocca W.A. Clinical correlates of the pathology underlying parkinsonism: a population perspective // Mov. Disord. 2002. — Vol. 17. — P. 910−916
- Bras J.M., Singleton A. Genetic susceptibility in Parkinson’s disease // Biochim Biophys Acta. -2009. Vol.1792. — P.597−603
- Bredesen D.E., Rao R.V., Mehlen P. Cell death in the nervous system // Nature. 2006. — Vol.443, № 7113. — P.796−802
- Brighina L., Prigione A., Begni B., Galbussera A., Andreoni S., Piolti R., Ferrarese C. Lymphomonocyte alpha-synuclein levels in aging and in Parkinson disease // Neurobiol Aging. 2010. — Vol.31. -P.884−5
- Brochard V., Combadiere B., Prigent A., et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease // Clin Invest. 2009. — Vol. 119, № 1. — P. 182−192
- Brooks A.I., Chadwick C.A., Gelbard H.A., et al. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss // Brain Research. 1999.-Vol.823. P. l-10
- Brooks D.J. The early diagnosis of Parkinson’s disease // Ann Neurol. -1998. Vol.44, Supp.l. — P. S10-S18
- Bueler H. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson’s disease // Exp Neurol. 2009. — Vol.218, № 2. -P.235−46
- Cabin D.E., Shimazu K., Murphy D., et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein // J Neurosci. 2002. — Vol.22. — P.8797−8807
- Calopa M., Bas J., Callen A., Mestre M. Apoptosis of peripheral blood lymphocytes in Parkinson patients // Neurobiol- Dis. 2010. — Vol.38, № 1. -P. 1 -7
- Chandra S., Gallardo G., Fernandez-Chacon R., Schluter O.M., Sudhof TC. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration // Cell. 2005. — Vol.123, № 33. -P.383−96
- Chen M., Wang J. Gaucher disease: review of the literature //Arch Pathol Lab Med. 2008. — Vol. 132, № 5. — P.851−3
- Chen Q., Book M., Fang X., Hoeft A., Stuber F. Screening of copy number polymorphisms in human beta-defensin genes using modified real-time quantitative PCR.//.J Immunol Methods. 2006. — Vol.308. — P. 231−40
- Choi J.H., Velayati A., Stubblefield B.K., Orr-Urtreger A., Gan-Or Z., Tayebi N., Sidransky E. False-Positive Results Using a Gaucher Diagnostic Kit -RecTL and N370S // Mol Genet Metab. 2010. — Vol. 100, № 1. — P. 100−102
- Choi J.H., Stubblefield B., Cookson M.R., Goldin E., Velayati A., Tayebi N., Sidransky E. Aggregation of a-synuclein in brain sa mples from subjects with glucocerebrosidase mutations // Mol Genet Metab. 2011. -Vol.104, № 1−2.-P.185−8
- Choi W.S., Kruse S.E., Palmiter R.D., Xia Z. Mitochondrial complex I inhibition is not required for dopaminergic neuron death induced by rotenone, MPP+, or paraquat // Proc Natl Acad Sci USA.- 2008. Vol. 105,№ 39. -P.15 136−41
- Clark I.E., Dodson M.W., Jiang C., Cao J.H., Huh J.R., Seol J.H., Yoo S.J., Hay B.A., Guo M. Drosophila pinkl is required for mitochondrial function and interacts genetically with parkin // Nature. 2006. -Vol.441, № 7097. -P. 1162−6
- Colombo C., Cosentino M., Marino F. Dopaminergic modulation of apoptosis in human peripheral blood mononuclear cells // Ann N Y Acad Sci. -2003.-Vol.1010.-P.679−682
- Conway K.A., Harper J.D., Lansbury P.T. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease // Nat Med. 1998. — Vol.4. -P.1318−1320
- Cookson M.R., Bandmann O. Parkinson’s disease: insight from pathways // Hum Mol Genet. 2010. — Vol.19. — P. R21-R27
- Cookson M.R. A feedforward loop links Gaucher and Parkinson’s disease // Cell. 2011. — Vol.146. — P. 9−11
- Cookson M.R., van der Brug M. Cell systems and the toxic mechanism (s) of alpha-synuclein // Exp Neurol. 2008. — Vol.209. — P.5−11
- Cosentino M., Marino F., Bombelli R., Ferrari M., Lecchini S., Frigo G. Endogenous catecholamine synthesis, metabolism, storage and uptake in human neutrophils // Life Sci. 1999. — Vol. 64, № 11. — P.975−81
- Covy J.P., Yuan W., Waxman E.A., Hurtig H.I., Van Deerlin V.M., Giasson B.I. Clinical and pathological characteristics of patients with leucine-rich repeat kinase-2 mutations // Mov Disord. 2009. — Vol.24, № 1. — P.32−9
- Cuervo A.M., Stefanis L., Fredenburg R., Lansbury P. T, Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy // Science. 2004. — Vol.305. — P. 1292−5
- Davidson W.S., Jonas A., Clayton D.F., George J.M. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes // J Biol Chem. 1998. — Vol.273. -P.9443−9449
- Dawson T.M. Parkinson’s Disease Genetics and Pathogenesis. New York: Informa healthcare USA, 2007. — 398p.
- Dawson T.M., Dawson V.L. Molecular pathways of neurodegeneration in Parkinson’s disease // Science. 2003. — Vol.302. — P.819−822
- De Marco E.V., Annesi G., Tarantino P., Nicoletti G., Civitelli D., Messina D., Annesi F., Arabia G., Salsone M., Condino F., Novellino F.,
- Provenzano G., Rocca F.E., Colica C., Morelli M., Scornaienchi V., Greco V., Giofre L., Quattrone A. Glucocerebrosidase gene mutations are associated with Parkinson’s disease in southern Italy // Mov Disord. 2008. — Vol.23, № 3. -P.460−3
- Dekker M.C., Eshuis S.A., Maguire R.P., Veenma-van der Duijn L., Pruim J., Snijders P.J., Oostra B.A., van Duijn C.M., Leenders K.L. PET neuroimaging and mutations in the DJ-1 gene // J Neural Transm. 2004. -Vol.111, № 12. -P.1575−81
- DePaolo J., Goker-Alpan O., Samaddar T., Lopez G., Sidransky E. The association between mutations in the lysosomal protein glucocerebrosidase and parkinsonism // Mov Disord. 2009. — Vol.24. — P. 1571−1578
- Dunnett S.B., Bjorklund A. Prospects for new restorative and neuroprotective treatments in Parkinson’s disease // Nature. 1999. — Vol.399, № 6738,Suppl. — P. A32−9
- Eberhardt O., Schulz J.B. Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson’s disease // Toxicol Lett. 2003. -Vol.139, № 2−3.-P.135−51
- Elbaz A., Alperovitch A. Bias in association studies resulting from gene-environment interactions and competing risks // Am J. Epidemiol. 2002. -Vol.155.-P.265−272
- Elbaz A. LRRK2: bridging the gap between sporadic and hereditary Parkinson’s disease,// Lancet Neurol.- 2008.- Vol. 7.-P.562−4
- Elenkov I.J., Wilder R.L., Chrousos G.P., Vizi E.S. The sympathetic nerve—an integrative interface between two supersystems: the brain and the immune system // Pharmacol. Rev. 2000. — Vol. 52. — P.595- 638
- Eller M., Williams D.R. a-Synuclein in Parkinson disease and other neurodegenerative disorders. Clin Chem Lab Med. 2011. — Vol.49, № 3. — P.403−8
- Falcone D.C., Wood E.M., Xie S.X., Siderowf A., Van Deerlin V.M. Genetic testing and Parkinson disease: assessment of patient knowledge, attitudes, and interest // J Genet Couns. 2011. — Vol.20, № 4. — P.384−95
- Farrer M., Maraganore D.M., Lockhart P., Singleton A., Lesnick T.G., de Andrade M., West A., de Silva R., Hardy J., Hernandez D. alpha-Synuclein gene haplotypes are associated with Parkinson’s disease // Hum Mol Genet. 2001. -Vol.10, № 17.-P. 1847−51
- Farrer M.J. Genetics of Parkinson’s disease paradigm shifts and future prospects // Nature Reviews. 2006. — Vol.7. — P. 306−318
- Feany M.B., Bender W.W. A drosophila model of Parkinson’s disease // Nature. 2000. — Vol.404. -P.394−398
- Flower T.R., Chesnokova L.S., Froelich C.A., Dixon C., Witt S.N. Heat shock prevents alpha-synuclein-induced apoptosis in a yeast model of Parkinson’s disease // J Mol Biol. 2005. — Vol.351, № 5. — P. 1081−100
- Franco R., Pacheco R., Lluis C., Ahern G.P., O Connell P.J. The emergence of neurotransmitters as immune modulators // Trends Immunol. 2007. — Vol.28. — P.40040
- Friedlander RM. Apoptosis and caspases in neurodegenerative diseases // N Engl J Med. 2003. — Vol.348, № 14. — 1365−75
- Fuchs J., Tichopad A., Golub Y., Munz M., Schweitzer K.J., Wolf B., Berg D., Mueller J.C., Gasser T. Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. // J. FASEB. 2008. — Vol.22, № 5. -P.1327−1334
- Fujita K., Nakabeppu Y., Noda M. Therapeutic effects of hydrogen in animal models of Parkinson’s disease // Parkinsons Dis. 2011. — Vol.2011. — P. 307 875
- Fukushima T., Yamada K, Hojo N, Isobe A, Shiwaku K, Yamane Y. Mechanism of cytotoxicity of paraquat. III. The effects of acute paraquat exposure on the electron transport system in rat mitochondria // Exp Toxicol Pathol. 1994. -Vol.46.-P.437141
- Funayama M., Hasegawa K., Kowa H., Saito M., Tsuji S., Obata F. A new locus for Parkinson’s disease (PARK8) maps to chromosome 12p 11.2-p 13.1. // Ann. Neurol. 2002. — Vol.51. — P.296−301
- Fung H.C., Chen C.M., Hardy J., Hernandez D., Singleton A., Wu Y.R. Lack of G2019S LRRK2 mutation in a cohort of Taiwanese with sporadic Parkinson’s disease // Mov Disord.- 2006.-Vol.21.-P.880−881
- Gasser T. Update on the Genetics of Parkinson’s Disease. // Mov. Disord. 2007. — Vol.22. — P. S343-S350
- Giasson B.I., Covy J.P.,. Bonini N. M, Hurtig H.I., Farrer M.J., Trojanowski J.Q., Van Deerlin V.M. Biochemical and pathological characterization of Lrrk2. //Ann.Neurol. 2006. — Vol. 59. — P.315−322
- Giasson B.I., Murray I.V., Trojanowski J.Q., Lee V.M. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly // J Biol Chem. 2001. — Vol.276. -P.2380−2386
- Giasson B.I., Van Deerlin V.M. Mutations in LRRK2 as a Cause of Parkinson’s disease. //Neurosignals. -2008. Vol.16. -P.99−105
- Giasson B.I., Covy J.P., Bonini N.M., Hurtig H.I., Farrer M.J., Trojanowski J.Q., Van Deerlin V.M. Biochemical and pathological characterization of Lrrk2 // Ann Neurol. 2006. — Vol.59. — P.315−322
- Giasson B.I., Duda J.E., Quinn S.M., Zhang B., Trojanowski J.Q., Lee V.M. Neuronal alphasynucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein // Neuron. 2002. — Vol.34. — P.521−533
- Gillardon F. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability a point of convergence in Parkinsonian neurodegeneration. // J Neurochem. — 2009. — Vol.110. — P. 15 141 522
- Ginsberg G., Neafsey P., Hattis D., Guyton K.Z., Johns D.O., Sonawane B. Genetic polymorphism in paraoxonase 1 (PON1): Population distribution of PON1 activity // J Toxicol Environ Health B Crit Rev. 2009.-Vol.12.- P.473−507
- Gispert S., Del Turco D., Garrett L., et al. Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol Cell Neurosci. 2003. — Vol.24. — P.419−429
- Gloeckner C. J., Schumacher A., Boldt K., Ueffmg M. The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. // J Neurochem. 2009. — Vol.109. — P.959−968
- Goker-Alpan O., Lopez G., Vithayathil J., Davis J., Hallett M., Sidransky E. The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations // Arch Neurol. 2008. — Vol.65, № 10. -P.1353−7
- Goker-Alpan O., Stubblefield B.K., Giasson B.I., Sidransky E. Glucocerebrosidase is present in a-synuclein inclusions in Lewy body disorders // Acta Neuropathol. 2010. — Vol.120, № 5. — P.641−9
- Gomez C., Bandez M.J., Navarro A. Pesticides and impairment of mitochondrial function in relation with the parkinsonian syndrome // Front Biosci. -2007.-Vol.12. -P.1079−93
- Pfeiffer RF, Uitti RJ, Stoessl AJ, Wszolek ZK, Farrer MJ, Mueller JC, Gasser T, Fuchs J. et al. Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice. Neurobiol Aging 2003- 24:245−258
- Gonzalez-Polo RA, Rodriguez-Martin A, Moran JM, Niso M., Soler G., Fuentes J.M. Paraquat-induced apoptotic cell death in cerebellar granule cells // Brain Res. 2004. — Vol.1011, № 2. -P. 170−176
- Greene J.C., Whitworth A.J., Kuo L, Andrews L.A., Feany M.B., Pallanck L.J. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants // Proc Natl Acad Sci USA.- 2003. Vol.100, № 7. -P.4078−83
- Greggio E., Cookson M.R. Leucine-rich repeat kinase 2 mutations and Parkinson’s disease: three questions // ASN Neuro. 2009. — Vol.1, № 1. — P. pii: e00002. doi: 10.1042/AN20090007
- Greggio E., Singleton A. Kinase signaling pathways as potential targets in the treatment of Parkinson’s disease. // Expert Review of Proteomics. -2007. Vol.4,Suppl.6. -P.783−792
- Greggio E., Bisaglia M., Civiero L., Bubacco L. Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson’s disease? Mol Neurodegener. 2011. — Vol.6. — P.6
- Gupta N., Oppenheim I.M., Kauvar E.F., Tayebi N., Sidransky E. Type 2 Gaucher disease: phenotypic variation and genotypic heterogeneity // Blood Cells Mol Dis. 2011. — Vol.46, № 1. -P.75−84
- Hanrott K., Gudmunsen L., O’Neill M.J., Wonnacott S. 6-hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidationand caspase 3-dependent activation of protein kinase Cdelta // J Biol Chem. -2006. Vol.281, № 9. — P.5373−82
- Hardy J. Genetics analysis of pathways to Parkinson’s disease // Neuron. -2010. Vol.68. — P.201−206
- Hardy J., Selkoe D.J. The amyloid hypotesis of Alzheimer’s diseaseA progress and problems on the road to therapeutics // Science. 2002. — Vol.297. -P.353−356
- Hartmann A., Hirsch E.C. Parkinson’s disease. The apoptosis hypothesis revisited // Adv Neurol. 2001. — Vol.86. — P. 143−53
- Hashimoto M., Rockenstein E., Masliah E. Transgenic models of alpha-synuclein pathology: past, present, and future // Ann NY Acad Sci. 2003. -Vol.991.-P.171−188
- Hattorf N., Mizuno Y. Pathogenetic mechanisms of parkin in Parkinson' Disease // Lancet. 2004. — Vol.364. -P.722−724
- Hayashi T., Ishimori C., Takahashi-Niki K., Taira T., Kim Y.C., Maita FI., Maita C., Ariga H., Iguchi-Ariga S.M. DJ-1 binds to mitochondrial complex I and maintains its activity // BBRC. 2009. — Vol.390. — P.667−672
- Healy D.G., Wood N.W., Schapira A.H. Test for LRRK2 mutations in patients with Parkinson’s disease// Pract Neurol. 2008. — Vol.8. — P.381−385.
- Hedrich K., Eskelson C., Wilmot B., Marder K., Harris J., Garrels J., Meija-Santana H., Vieregge P., Jacobs H., Bressman S.B., Lang A.E., Kann M.,
- Abbruzzese G., Martinelli P., Schwinger E., Ozelius .LJ., Pramstaller P.P., Klein C, Kramer P. Distribution, type, and origin of Parkin mutations: review and case studies // Mov Disord. 2004. — Vol.19, № 10. — P. 1146−57
- Hernan M.A., Zhang S.M., Rueda-deCastro A.M., Colditz G.A., Speizer F.E., Ascherio A. Cigarette smoking and the incidence of Parkinson’s disease in two prospective studies // Ann Neurol. 2001. — Vol.50. — P.780−786
- Hoehn M.M., Yarh H.D. Parkinsonism: Onset, Progression and Mortality // Neurology. 1967. — Vol.17. — P.427−442
- Horowitz M.P., Greenamyre J.T. Gene-environment interactions in Parkinson’s disease: the importance of animal modeling // Clin Pharmacol Ther. -2010. Vol.88, № 4. — P.467−74
- Hruska K.S., LaMarca M.E., Scott C.R., Sidransky E. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA) // Hum Mutat. 2008. — Vol.29, № 5.-P.567−83
- Huerta S., Goulet E.J., Huerta-Yepez S., Livingston E.H. Screening and detection of apoptosis // J Surg Res. 2007. — Vol.139, № 1. -P. 143−56
- Hughes A.J., Ben-Shlomo Y., Daniel S.E., Lees A.J. What features improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathologic study 1992 // Neurology. 2001. — Vol.57, № 10, Suppl 3. -P.S34−8
- Iaccarino C., Crosio C., Vitale C., Sanna G. Apoptotic mechanisms in mutant LRRK2-mediated cell death // Hum Mol Genetic. 2007. — Vol.16, № 11.- P. 1319−26
- Ibanez P., Bonnet A.M., Debarges B., Lohmann E., Tison F., Pollak P., Agid Y., Durr A., Brice A. Causal relation between alpha-synuclein gene duplication and familial Parkinson’s disease // Lancet. 2004. — Vol.364, № 9440. -P.l 169−71
- Imai Y., Gehrke S., Wang H. Q., Takahashi R., Hasegawa K., Oota E., Lu B. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila // EMBO J. 2008. — Vol. 27. — P.2432−2443
- Ishihara-Paul L., Hulihan M.M., Kachergus J., Upmanyu R., Warren L., Amouri R., Elango R., Prinjha R.K., Soto A., Kefi M., Zouari M., Sassi S.B.,
- Yahmed S.B., El Euch-Fayeche G., Matthews P.M., Middleton L.T., Gibson R.A., Hentati F., Farrer M.J. PINK1 mutations and parkinsonism // Neurology. 2008. -Vol.71, № 12.-P.896−902
- Jellinger K.A., Stadelmann C. Mechanisms of cell death in neurodegenerative disorders // J Neural Transm Suppl. 2000. — Vol.59. — P.95−114
- Jellinger K.A. Challenges in neuronal apoptosis // Curr Alzheimer Res. -2006.-Vol.3, № 4. P.377−91
- Johnson S.J., Wade-Martins R. A BACwards glance at neurodegeneration: molecular insights into disease from LRRK2, SNCA and MAPT BAC-transgenic mice // Biochem Soc Trans. 2011. — Vol.39№ 4. — P.862−7
- Josephs K.A., Joseph Y., Matsumoto J., Ahlskog E. Benign Tremulous Parkinsonism // Arch Neurol. 2006. — Vol.63. -P.354−357
- Katoh N., Soga F., Nara T., Tamagawa-Mineoka R., Nin M., Kotani H., Masuda K., Kishimoto S. Effect of serotonin on the differentiation of human monocytes into dendritic cells // Clin. Exp. Immunol. 2006. — Vol.146. — P.354−361
- Kawashima K., Fujii T. The lymphocytic cholinergic system and its contribution to the regulation of immune activity // Life Sci. 2003. — Vol.74. -P.675−696
- Khan N.L., Graham E., Critchley P., Schrag A.E., Wood N.W., Lees A.J., Bhatia K.P., Quinn N. Parkin disease: a phenotypic study of a large case series // Brain. -2003. Vol.126, Pt 6. — P. 1279−92
- Khan N.L., Scherfler C., Graham E., Bhatia K.P., Quinn N., Lees A.J., Brooks D.J., Wood N.W., Piccini P. Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation // Neurology. 2005. — Vol.64, № 1,-P. 134−6
- Kawashima K., Fujii T. The lymphocytic cholinergic system and its contribution to the regulation of immune activity // Life Sci. 2003. — Vol.74, № 6. -P.675−96
- Kim H.J., Kim H.J., Lee J.Y., Yun J.Y., Kim S.Y., Park S.S., Jeon B.S. Phenotype analysis in patients with early onset Parkinson’s disease with and without parkin mutations // J Neurol. 2011. — Vol.258, № 12. — P.2260−7
- Kim S., Seong M., Jeon B., Kim S., Ko H., Kim J., Park S. Phase analysis identifies compound heterozygous deletions of the PARK2 gene in patients with early-onset Parkinson disease // Clin Genet. 2011. — doi: 10.1111/j.l 399−0004.2011.1 693 .x
- Kim Y., Park J., Kim S., Song S., Kwon S.K., Lee S.H., Kitada T., Kim J.M., Chung J. PINK1 controls mitochondrial localization of Parkin through direct phosphorylation // BBRC. 2008. — Vol.377. — P.975−980
- Kimura H., Kurimura M., Wada M., Kawanami T., Kurita K., Suzuki Y., Katagiri T., Daimon M., Kayama T., Kato T. Female preponderance of Parkinson’s disease in Japan // Neuroepidemiology. 2002. — Vol.21, № 6. — P.292
- Kitada T., Pisani A., Karouani M., Haburcak M., Martella G., Tscherter A., Platania P., Wu B., Pothos E.N., Shen J. Impaired dopamine release and synaptic plasticity in the striatum of parkin-/- mice // J Neurochem. 2009. -Vol.110, № 2.-P.613−21
- Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., Shimizu N. Mutation in the parkin gene cause autosomal recessive juvenile parkinsonism // Nature. 1998. — Vol.392. -P.605−608
- Klein C., Chuang R., Marras C.- Lang A.E. The curious case of phenocopies in families with genetic Parkinson’s disease // Mov Disord. 2011. -Vol.26, № 10.-P.1793−802
- Klein C., Djarmati A. Parkinson disease: genetic testing in Parkinson disease-who should be assessed? Nat Rev Neurol. 2011. — P.7, № 1. -P.7−9
- Kruger R., Kuhn W., Muller T. Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., Riess O. Ala30Pro mutation in the gene encoding alphasynuclein in Parkinson’s disease // Nat Genet. 1998. — Vol. 18, № 2. — P. 106−108
- Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage «1 «4 // Nature (Lond.). 1970. — Vol.227. — P.680−685
- Lander E.S. Initial impact of sequencing of the human genom // Nature. -2011. Vol.470. -P.187−197
- Lasage S., Brice A. Parkinson’s disease: from monogenic forms to genetic susceptibility factors // Hum Molec Genet. 2009. — Vol.18, № 1. — P. R48-R59
- Lee F.J.S., Liu F., Pristupa Z.B., Niznik H.B. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis // Faseb J. 2001. — Vol.15. — P.916−926
- Lee J.A. Autophagy in neurodegeneration: two sides of the same coin // BMB Rep. 2009. — Vol.42, № 6. — P.324−30
- Lee P.H., Lee G., Park H.J., Bang O.Y., Joo I.S., Huh K. The plasma alpha-synuclein levels in patients with Parkinson’s disease and multiple system atrophy // J Neural Transm. 2006. — Vol.13. — P. 1435−9
- Lee S.J. Origins and effects of extracellular alpha-synuclein: implications in Parkinson’s disease // J Mol Neurosci. 2008. — Vol.34, № 1. -P. 17−22
- Leon-Ponte M., Ahern G.P., O Connell P.J. Serotonin provides an accessory signal to enhance T-cell activation by signaling through the 5-HT7 receptor // Blood. 2007. — Vol. 109. — P.3139−3146
- Lesage S., Lohmann E., Tison F., Durif F., Diirr A., Brice A. Gene symbol: PARK2. Disease: Parkinsonism, juvenile, autosomal recessive // Hum Genet. 2008. — Vol.123, № 1. — P. l 14
- Li M.J., Wang P., Liu X., Lim E.L., Wang Z., Yeager M., Wong M.P., Sham P.C., Chanock S.J., Wang J. GWASdb: a database for human genetic variants identified by genome-wide association studies // Nucleic Acids Res. -2012. Vol.40. — P. D1047−54
- Li Q.X., Mok S.S., Laughton K.M., McLean C.A., Cappai R., Masters C.L., Culvenor J.G., Home M.K. Plasma alpha-synuclein is decreased in subjects with Parkinson’s disease // Exp Neurol. 2007. — Vol.204, № 2. — P.583−588
- Lichuan Y., Kesheng Z., Calingasan N.Y., Luo G., Szeto H.H., Beal M.F. Mitochondria Targeted Peptides Protect Against l-Methyl-4-Phenyl-l, 2,3,6-Tetrahydropyridine Neurotoxicity // Antioxid Redox Signal. 2009. — Vol.11, № 9.-P. 2095−2104
- Lucking C.B., Chesneau V., Lohmann E,. Verpillat P., Dulac C., Bonnet A.M., Gasparini F., Agid Y., Diirr A., Brice A. Coding Polymorfisms in the Parkin Gene and Susceptibility to Parkinson Disease // Arch Neurol. 2003. -Vol.60.-P.1253−1256
- Luk K.C., Song C., O’Brien P., Stieber A., Branch J.R., Brunden K.R., Trojanowski J.Q., Lee V.M. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells // PNAS. 2009. — Vol. 106.-P.20 051−6
- Lwin A., Orvisky E., Goker-Alpan O., LaMarca M.E., Sidransky E. Glucocerebrosidase mutations in subjects with parkinsonism // Mol Genet Metab. -2004, — Vol.81, №l.-P.70−3
- Mackness M.I., Mackness B., Durrington P.N., Connelly P.W., Hegele R.A. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins // Curr Opin Lipidol. 1996. — Vol.7.- P.69−76
- Macleod D., Dowman J., Hammond R., Leete T., Inoue K., Abeliovich
- A. The familial Parkinsonism gene LRRK2 regulates neurite process morphology // Neuron. 2006. — Vol.52, № 4. -P.587−93
- Manning-Bog A.B., Schiile B., Langston J.W. Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism // Neurotoxicology. 2009. -Vol.30№ 6. — P. 1127−32
- Manthripragada A.D., Costello S., Cockburn M.G., Bronstein J.M., Ritz
- B. Paraoxonase 1, agricultural organophosphate exposure, and Parkinson disease // Epidemiology.- 2010, — Vol.21.- P.87−94
- Maraganore D.M., de Andrade M., Elbaz A., Farrer M.J., Ioannidis J.P., Kriiger R., Rocca W.A., Schneider N.K., Lesnick T.G., Lincoln S.J., Hulihan M.M., Aasly J.O., Ashizawa T., Chartier-Harlin M.C., Checkoway H., Ferrarese
- C., Hadjigeorgiou G., Hattori N., Kawakami H., Lambert J.C., Lynch T., Mellick G.D., Papapetropoulos S., Parsian A., Quattrone A., Riess O., Tan E.K., Van Broeckhoven C- Genetic Epidemiology of Parkinson’s Disease (GEO-PD)
- Consortium. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease // JAMA. 2006. — Vol. 296. — P.661−70
- Marder K., Levy G., Louis E.D., Mejia-Santana H., Cote L., Andrews PL, Harris J., Waters C., Ford B., Frucht S., Fahn S., Ottman R. Familial aggregation of early- and late-onset Parkinson’s disease // Ann Neurol. 2003. -Vol.54, № 4. -P.507−13
- Maries E., Dass B., Collier T.J., Kordower J.H., Steece-Collier K. The role of alpha-synuclein in Parkinson’s disease: insights from animal models // Nat Rev Neurosci. 2003. — Vol.4, № 9. — P.727−38
- Marino F., Cosentino M., Bombelli R., Ferrari M., Lecchini S., Frigo G. Endogenous catecholamine synthesis, metabolism storage, and uptake in human peripheral blood mononuclear cells // Exp Hematol. 1999. — Vol.27, № 3. -P.489−95
- Markoff A., Savov A., Vladimirov V., Bogdanova N., Kremensky I., Ganev V. Optimization of single-strand conformation polymorphism analysis in the presence of polyethylene glycol // Clin Chem. 1997. — Vol.43, № 1. — P.30−3
- Maroteaux L., Campanelli J.T., Scheller R.H. Synuclein — a neuron-specific protein localized to the nucleus and presynaptic nerve-terminal // J Neurosci. 1988.-Vol.8.-P.2804−2815
- Martin L.J., Pan Y., Price A.C., Sterling W., Copeland N.G., Jenkins N.A., Price D.L., Lee M.K. Parkinson’s disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death // J Neurosci. 2006. -Vol.26.-P.41−50
- Maruyama M., Ikeuchi T., Saito M., Ishikawa A., Yuasa T., Tanaka H., Hayashi S., Wakabayashi K., Takahashi H., Tsuji S. Novel Mutation, Pseudo
- Dominant Inheritance, and Possible Familial Affects in Patients with Autosomal Recessive Juvenile Parkinsonism // Ann Neurol. 2000. — Vol 48, № 2. — P245−250
- Mazzulli J.R., Xu Y., Sun Y., et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleopathies // Cell. 2011. V.146. P.37−52
- McCarthy S., Somayajulu M., Sikorska M., Borowy-Borowski H., Pandey S. Paraquat induces oxidative stress and neuronal cell death- neuroprotection by’water-soluble coenzyme Q (10) // Toxicol Appl Pharmacol. -2004.-Vol.201.-P.21−31
- McCormack A.L., Atienza J.G., Johnston L.C., Andersen J.K., Vu S., Di Monte D.A. Role of oxidative stress in paraquat-induced dopaminergic cell degeneration // J Neurochem. 2005. — Vol.93. — P.1030−1037
- McGeer P.L., McGeer E.G. Glial reactions in Parkinson’s disease // Mov Disord. 2008. — Vol.23, № 4. — P.474−83
- Mclnerney A., Hadley D.W., Gwinn-Hardy K., Hardy J. Genetic testing in Parkinson’s disease // Mov Disord. 2005. — Vol.20. — P.1−10
- Michell A.W., Luheshi L.M., Barker R.A. Skin and platelet alpha-synuclein as peripheral biomarkers of Parkinson’s disease // Neurosci Lett. 2005. — Vol.381,№ 3.-P.294−8
- Miller D.W., Hague S.M., Clarimon J., Baptista M., Gwinn-FIardy K., Cookson M.R., Singleton A.B. Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication // Neurology. 2004. — Vol.62, № 10.-P.1835−1838
- Milosevic J., Schwarz S.C., Ogunlade V., Meyer A.K., Storch A., Schwarz J. Emerging role of LRRK2 in human neural progenitor cell cycle progression, survival and differentiation // Mol Neurodegener. 2009. — Vol.4.-P.25
- Moos T., Jensen P.H. Absence of prostate apoptosis response-4 protein in substantia nigra of Parkinson’s, disease autopsies // Acta Neuropathol. -2004. Vol. l07№l. — P.23−6
- Nakano K., Higashi T., Takagi R., Hashimoto K., Tanaka Y., Matsushita S. Dopamine released by dendritic cells polarizes Th2 differentiation // Int. Immunol. 2009. — Vol.21, № 6. — P.645−654
- Narendra D., Tanaka A., Suen D.F., Youle R.J. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy // J Cell Biol. -2008. Vol.183, № 5. — P.795−803
- Nemani V.M., Lu W., Berge V., Nakamura K., Onoa B., Lee M.K., Chaudhry F.A., Nicoll R.A., Edwards R.H. // Neuron. 2010. — Vol.65. — P.66−79
- Neudorfer O., Giladi N., Elstein D., Abrahamov A., Turezkite T., Aghai E., Reches A., Bembi B., Zimran A. Occurrence of Parkinson’s syndrome in type I Gaucher disease // QJM. 1996. — Vol.89, № 9. — P.691−4
- Nicholl D.J., Bennett P., Hiller L., Bonifati V., Vanacore N., Fabbrini G., Marconi R., Colosimo C., Lamberti P., Stocchi F., Bonuccelli U., Vieregge P., Ramsden D.B., Месо G., Williams A.C. A study of five candidate genes in
- Parkinson’s disease and related neurodegenerative disorders- European Study Group on Atypical Parkinsonism // Neurology. 1999. — Vol.53, № 7. — P.1415−21
- O’Connell P.J., Wang X., Leon-Ponte M., Griffiths C., Pingle S.C., Ahern G.P. A novel form of immune signaling revealed by transmission of the inflammatory mediator serotonin between dendritic cells and T cells // Blood. -2006. Vol.107.-P.1010−101
- Ohta E., Kubo M., Obata F. Prevention of intracellular degradation of I2020T mutant LRRK2 restores its protectivity against apoptosis // Biochem Biophys Res Commun. 2010. — Vol.391№ 1. — P.242−7
- Olanow C.W., McNaught K. Parkinson’s disease, proteins, and prions: milestones // Mov Disord. 2011. — Vol.26№ 6. — P. 1056−71
- Oyama G., Yoshimi K., Natori S., Chikaoka Y., Ren Y.R., Funayama M., Shimo Y., Takahashi R., Nakazato T., Kitazawa S., Hattori N. Impaired invivo dopamine release in parkin knockout mice // Brain Res. 2010. — Vol.17, № 1352. — P.214−22
- Pacheco R., Prado C.E., Barrientos M.J., Bernales S. Role of dopamine in the physiology of T-cells and dendritic cells // J Neuroimmunol. 2009. -Vol.216№l-2. — P.8−19
- Pacheco R., Ciruela F., Casado V., Mallol J., Gallart T., Lluis C., Franco R. Group I metabotropic glutamate receptors mediate a dual role of glutamate in T cell activation // J. Biol. Chem. 2004. — Vol.279. — P.33 352−33 358
- Pacheco R., Gallart T., Lluis C., Franco R. Role of glutamate on T-cell mediated immunity // J. Neuroimmunol. -2007. Vol.185. — P.9−19
- Paisan-Ruiz C., Jain S., Evans E.W., Gilks W., Simon J., van der Brug M., de Munain A ., Aparicio S., Gil A., Khan N. Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease // Neuron. 2004. — Vol. 44. — P.595−600
- Palacino J.J., Sagi D., Goldberg M.S., Krauss S., Motz C., Wacker M., Klose J., Shen J. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice // J Biol Chem. 2004. — Vol.279, № 18. — P. 18 614−22
- Parkinson J. An essay on the shaking palsy // J Neuropsychiatry Clin Neurosci. 2002, — Vol. 14. — P.223−236
- Payami H., Larsen K., Bernard S., Nutt J.G. Increased risk of Parkinson’s disease in parents and siblings of patients // Am Neurol. 1994. -Vol.36, № 4,-P.659−661
- Pchelina S. N., Yakimovskii A. F., Ivanova O. N., Emelianov A. K., Zakharchuk A. FI., Schwarzman A. L. G2019S LRRK2 Mutation in Familial and Sporadic Parkinson’s Disease in Russia // Mov Disord. 2006. — Vol.21, № 12. -P.2234−2236
- Peng J., Mao X.O., Stevenson F.F., Hsu M., Andersen J.K. The herbicide paraquat induces dopaminergic nigral apoptosis through sustained activation of the JNK pathway // J Biol Chem. r 2004. Vol.279, № 31. — P.32 626−32
- Perez R., Waymire JC, Lin E, Liu J.J., Guo F., Zigmond M.J. A role for alpha-synuclein in the regulation of dopamine biosynthesis // J Neurosci. 2002. -Vol.22.-P.3090−3099
- Perez R.G., Hastings T.G. Could a loss of alpha-synuclein function put dopaminergic neurons at risk? J Neurochem. -2004. Vol.89, № 6. — P. 1318−24
- Periquet M., Fulga T., Myllykangas L., Schlossmacher M.G., Feany M.B. Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo // J Neurosci. 2007. — Vol.27№ 12. — P.3338−46
- Pirkevi C., Lesage S., Brice A., Ba§ ak A.N. From genes to proteins in mendelian Parkinson’s disease: an overview // Anat Rec (Hoboken). 2009. -Vol.292, № 12. -P.1893−901
- Plowey E.D., Chu C.T. Synaptic dysfunction in genetic models of Parkinson’s disease: a role for autophagy? Neurobiol Dis. 2011. — Vol.43, № 1. -P.60−7
- Polwey E.D., Cherra S.J., Liu Y., Chu C, T. Role of autophagy in G2019S-LRRK2-associated neurite shortenibg in differentiated SH-SY5Y cells // J Neurocem. 2008. — Vol.105. — P.1048−1056
- Poorkaj P., Bird T.D., Wijsman E., Nemens E., Garruto R.M., Anderson L., Andreadis A., Wiederholt W.C., Raskind M., Schellenberg G.D. Tau is a candidate gene for chromosome 17 frontotemporal dementia // Ann Neurol.1998.-Vol.43, № 6.-P.815−25
- Popescu B. O., Toescu E. C., Popescu L. M., Bajenaru O., Muresanu D. F., Schultzberg M., Bogdanovic, N. Blood-brain barrier alterations in ageing and dementia//J. Neurol. Sci. -2009. Vol.283. -P.99−106
- Poulopoulos M., Levy O.A., Alcalay R.N. The neuropathology of genetic Parkinson’s disease // Mov Disord. 2012. — doi: 10.1002/mds.24 962
- Priyardarshi A., Khuder S.A., Schaub E.A., Shrivastava S. A metaanalysis of Parkinson’s disease and exposure to pesticides // Neurotoxicology. -2000. Vol.21, № 4. — P.435−440
- Qi Z., Yang W., Liu Y., Cui T., Gao H., Duan C., Lu L., Zhao C., Zhao H., Yang H. Loss of PINK1 function decreases PP2A activity and promotes autophagy in dopaminergic cells and a murine model // Neurochem Int. 2011. -Vol.59, № 5.-P.572−81
- Qing H., Wong W., McGeer E.G., McGeer P.L. Lrrk2 phosphorylates alpha-synuclein at serine 129: Parkinson disease implications // BBRC. 2009. -Vol.387.-P.149−152
- Rajda C., Dibo G, Vecsei L, Bergquist J. Increased dopamine content in lymphocytes from high-dose L-Dopa-treated Parkinson’s disease patients // Neuroimmunomodulation. 2005. — Vol.12, № 2. — P.81−84
- Ramachandiran S., Hansen J.M., Jones D.P., Richardson J.R., Miller G.W. Divergent mechanisms of paraquat, MPP+, and rotenone toxicity: oxidation of thioredoxin and caspase-3 activation // Toxicol Sei. 2007. — Vol.95 № 1. -P.163−71
- Rocca W.A., McDonnell S.K., Strain K.J., Bower J.H., Ahlskog J.E., Elbaz A., Schaid D. J, Maraganore D.M. Familial aggregation of Parkinson’s disease: The Mayo Clinic family study // Ann Neurol. 2004. — Vol.56, № 4. -P.495−502
- Roho C.F., Montagna P., Breedveld G. Cortelli P., Oostra B.A., Bonifati V. Homozygous PINK1 C-Terminus mutation causing early-onset parkinsonism // Ann Neurol. 2004. — Vol.56. — P.427−431
- Rosen A., Casciola-Rosen L. Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease // Cell death and differentiation. 1999. — Vol.6. — P.6−12
- Ruiz-Ponte C., Carracedo A., Barros F. Duplication and deletion analysis by fluorescent real-time PCR-based genotyping // Clin Chim Acta. -2006. Vol.363, № 1−2.-P.138−46
- Salmon M., Gordon C. The role of apoptosis in systemic lupus erythematosus // Rheumatology. 1999. — Vol.38. — P. l 177−1183
- Savitt M., Dawson V.L., Dawson T.M. Diagnosis and treatment of Parkinson’s disease: molecules to medicine // J Clin Investigation. 2006. -Vol.116.-P.1744−1754
- Schaefer S., Vogt T., Nowak T., Kann P.H., German KIMS board. Pituitary function and the somatotrophic system in patients with idiopathic
- Parkinson’s disease under chronic dopaminergic therapy // J Neuroendocrinol. -2008 -Vol.20, № 1.-P. 104−109
- Shapira A.H., Gegg M. Mitochondrial contribution to Parkinson’s disease pathgenesis // Parkinson’s disease. 2011. — Vol.2011, ID 159 160. — P.7
- Shapiro H.M. (Ed.). Practical Flow Cytometry, 4 ed. 2003, New York: John Wiley & Sons Inc. — 736p
- Shimura H., Hattori N., Kubo S. et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase // Nature Genet. 2000. — Vol.25. -P.302−305.
- Shimura H., Hattori N., Kubo S., Mizuno Y., Asakawa S., Minoshima S., Shimizu N., Iwai K., Chiba T., Tanaka K., Suzuki T. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase // Nature Genet. 2000. -Vol.25.-P.302−305
- Shulman J.M., DeJager P.L., Feany M.B. Parkinson’s disease: Genetics and Pathogenesis // Ann Rev Pathol Mech. 2011. — Vol.6. — P. 193−222
- Shults C.W., Barrett J.M., Fontaine D. alpha-synuclein from platelets is not phosphorylated at serine 129 in Parkinson’s disease and multiple system atrophy // Neurosci Lett. 2006. — Vol.405, № 3. — P.223−5
- Shults C.W., Rockenstein E., Crews L., Adame A., Mante ML, Larrea
- Sidransky E., Nails M.A., Aasly J.O., Aharon-Peretz J., Annesi G., Barbosa E.R., Bar-Shira A., Berg D., Bras J., Brice A., Chen C.M., Clark L.N., Condroyer C., De Marco E.V., Durr A., Eblan M.J., Fahn S., Farrer M.J., Fung
- H.C., Gan-Or Z., Gasser T., Gershoni-Baruch R., Giladi N., Griffith A., Gurevich T., Januario C., Kropp P., Lang A.E., Lee-Chen G.J., Lesage S., Marder K., Mata
- Sidransky E., Samaddar T., Tayebi N. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset // Neurology. -2009.- Vol.73, № 17. -P. 1424−5
- Sidransky E. Gaucher disease: complexity in a «simple» disorder // Mol Genet Metab. 2004. — Vol.83, № 1−2. — P.6−15
- Singh M., Khan A.J., Shah P.P., Shukla R., Khanna V.K., Parmar D. Polymorphism in environment responsive genes and association with Parkinson disease // Mol Cell Biochem. 2008. — Vol.312, .№ 1−2. — P.131−8
- Singleton A. What does PINK1 mean for Parkinson disease? Neurology. 2004. — Vol.63. — P. 1350−1351
- Smith W. W., Pei Z., Jiang H., Dawson V. L., Dawson T. M., Ross C. A. Kinase activity of mutant LRRK2 mediates-neuronal toxicity // Nat Neurosci. -2006. Vol. 9.-P.1231−1233
- Smith W.W., Pei Z., Jiang H., Dawson V.L. Kinase activity of mutant LRRK2 mediates neuronal toxicity // Nat Neurosci. 2006. — Vol.10. — P. 12 311 233
- Sogorb M.A., Vilanova E. Enzymes involved in the detoxification of organophosphorus, carbamate and pyrethroid insecticides through hydrolysis // Toxicol Lett.- 2002.-Vol.128, — P.215−28
- Sorge J., West C., Westwood B., Beutler E. Molecular cloning and nucleotide sequence of human glucocerebrosidase cDNA // Proc Natl Acad Sci U S A. 1985. — Vol.82, № 21. — P.7289−93
- Spillantini M.G., Schmidt M.L., Lee VMY, Trojanowski J.Q., Jakes R., Goedert M. Alph-asynuclein in Lewy bodies // Natureio 1997. — Vol. 388. -P.839−840
- Tan E.K., Chandran V.R., Fook-Chong S., Shen H., Yew K., Teoh M.L., Yuen Y., Zhao Y. Alpha-synuclein mRNA expression in sporadic Parkinson’s disease // Mov Disord. 2005. — Vol.20, № 5. — P.620−623
- Tan E.K., Khajavi M., Thornby J.I., Nagamitsu S., Jankovic J., Ashizawa T. Variability and validity of polymorphism association studies in Parkinson’s disease,// Neurology. 2000. — Vol.55, № 4. — P.533−8
- Tanji K., Mori F., Kakita A., Takahashi H., Wakabayashi K. Alteration of autophagosomal proteins (LC3, GABARAP and GATE-16) in Lewy body disease // Neurobiol Dis. 2011. — Vol.43. — P.690−7
- Tatti M., Motta M., Salvioli R. Autophagy in Gaucher disease due to saposin C deficiency // Autophagy. 2011. — Vol.7. — P.94−5
- Tatton N.A. Incresed caspase 3 and BAX immunoreactivity accompany nuclear GAPGH translocation and neuronal apoptosis in Parkinson disease // Exp. Neurol. 2000 — Vol.166. — P. 29−43
- Tatton W.G., Chalmers-Redman R., Brown D., Tatton N. Apoptosis in Parkinson’s disease: signals for neuronal degradation // Ann Neurol. 2003. -Vol.53, Suppl 3. — P. S61−70
- Tawara T., Fukushima T., Hojo N., Isobe A., Shiwaku K., Setogawa T., Yamane Y. Effects of paraquat on mitochondrial electron transport system and catecholamine contents in rat brain // Arch Toxicol. 1996. — Vol.70. — P.585−589
- Taymans J., Cookson M.R. Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, alpha-synuclein, and tau // BioEssays. 2010. -Vol.32. — P.227−235
- Thiruchelvam M.J., Powers J.M., Cory-Slechta D.A., Richfield E.K. Risk factors for dopaminergic neuron loss in human alpha-synuclein transgenic mice // Eur J Neurosci. 2004. — Vol. 19. — P.845−854
- Tian, J., Lu Y., Zhang H., Chau C.H., Dang H.N., Kaufman D.L. Gamma-aminobutyric acid inhibits T cell autoimmunity and the development of inflammatory responses in a mouse type 1 diabetes model // J. Immunol. 2004. -Vol.173.-P.5298−5304
- Todes C.J., Lees A.J. The pre-morbid personality of patients with Parkinson’s disease // J Eur Neurosurg Psychiatry. 1985. — Vol.48. — P.97−100
- Tong Y., Pisani A., Martella G., Karouani M., Yamaguchi H., Pothos E.N., Shen J. R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice // Proc Natl Acad Sci USA.- 2009. Vol.106, № 34. -P. 14 622−7
- Tong Y., Shen J. Alpha-synuclein and LRRK2: Partnes in Crime // Neuron. 2009. — Vol.64. — P.771 — 773
- Trojanowski J.Q. Rotenone neurotoxicity: a new window on environmental causes of Parkinson’s disease and related brain amyloidoses // Exp Neurology. 2003. — Vol. 179. — P.6−8
- Tunner C.M., Ottoman R., Goldman S.M., Ellenberget J. Parkinson’s disease in twins: An etiologic study // JAMA. 1999. — Vol.281. — P.341−346
- Ueda K., Fukushima H., Masliah E., Xia Y., Iwai A., Yoshimoto M., Otero D.A., Kondo J, Ihara Y, Saitoh T. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease // PNAS. 1993. -Vol.90.-P.l 1282−11 286
- Vaux D.L., Flavell R.A. Apoptosis genes and autoimmunity. Curr Opin Immunol. -2000. Vol.12, № 6. — 719−24
- Velayati A., Yu W.H., Sidransky E. The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders // Curr Neurol Neurosci Rep. 2010. — Vol. 10, № 3. — P. 190−8
- Vernon A.C., Ballard C., Modo M. Neuroimaging for Lewy body disease: is the in vivo molecular imaging of a-synuclein neuropathology required and feasible? Brain Res Rev. 2010. — Vol.65. — P.28−55
- Vieregge P., Heberlein I. Increased risk of Parkinson’s disease in relatives of patients // Ann Neurol. 1995. — Vol.37, № 5. — P.685
- Vila M., Przedborski S. Genetic clues to the pathogenesis of Parkinson’s disease // Nature Med. 2004. — Vol.10. — P. S58-S62
- Wang M.S., Boddapati S., Emadi S., Sierks M.R. Curcumin reduces a-synuclein induced cytotoxicity in Parkinson’s disease cell model // BMC Neurosci. -2010.-Vol.ll.-P.57
- Watanabe Y., Nakayam T., Nagakubo D., LIieshima K., Jin Z., Katou F., Hashimoto K., Yoshie O. Dopamine selectively induces migration and homing of naive CD8+ T cells via dopamine receptor D3 // J Immunol. 2006. — Vol.176. — P.848−856
- Waxman E.A., Giasson B.I. A novel, high-efficiency cellular model of fibrillar alpha-synuclein inclusions and the examination of mutations that inhibit amyloid formation // J Neurochem. 2010. — Vol.113. — P.374−88
- White L.R., Toft M., Kvam S.N., Farrer M.J., Aasly, J.O. MAPK-pathway activity, Lrrk2 G2019S, and Parkinson’s disease // J Neurosci Res 2007. — Vol.85.-P.1288−1294
- Xiongwei Z., Babar A., Siedlak S.L., Yang Q., Ito G., Iwatsubo T., Smith M.A., Perry G., Chen S.G. LRRK2 in Parkinson’s disease and dementia with Lewy bodies // Molecular Neurodegeneration. 2006. — Vol.1. — P. 17
- Xu J., Kao S.Y., Lee F.J., Song W., Jin L.W., Yankner B.A. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease // Nat Med. 2002. — Vol.8, № 6. — P.600−6
- Xu P.Y., Liang R., Jankovic J., Hunter C., Zeng Y.X., Ashizawa T., Lai D., Le W.D. Association of homozygous 7048G7049 variant in the intron six of Nurrl gene with Parkinson’s disease // Neurology. 2002. — Vol.58, № 6. — P.881−4
- Yamada M., Kida K., Amutuhaire W., Ichinose F., Kaneki M. Gene disruption of caspase-3 prevents MPTP-induced Parkinson’s disease in mice // Biochem Biophys Res Commun. 2010. — Vol.402, № 2. — P.312−8
- Yamamura Y. The long journey to the discovery of PARK2 // Neuropathology. 2010. — PMID: 20 667 007
- Yang Q., She H., Gearing M., Colla E., Lee M., Shacka J.J., Mao Z. Regulation of neuronal survival factor MEF2D by chaperone-mediated autophagy // Science. 2009. — Vol.323. — P. 124−7
- Yang Q., Mao Z. Parkinson disease: a role for autophagy // Neuroscientist.- 2010 Vol.16, № 4, — P. 335−341
- Yap T.L., Gruschus J.M., Velayati A., Westbroek W., Goldin E., Moaven N., Sidransky E., Lee J.C. Alpha-synuclein interacts withdiseases // J Biol Chem. -2011.- Vol.286, № 32. P.28 080−8
- Youle R.J., Narendra D.P. Mechanisms of mitophagy // Nature Rev., 2011, V.12. P.9−14
- Zhou W., Zhu M., Wilson M.A., Petsko G.A., Fink A.L. The oxidative state of DJ-1 regulates its chaperone activity toward alpha-synuclein // J Mol Biol. 2006. — Vol.356. — P.1036−1048
- Zimprich A., Biskup S., Leitner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R., Calne D. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology // Neuron. 2004. — Vol. 44. — P.601−607
- Zintzaras E., Hadjigeorgiou G.M. Association of paraoxonase 1 gene polymorphisms with risk of Parkinson’s disease: a meta-analysis // J Hum Genet. -2004. Vol.49, № 9. — P.474−81